MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations
Last Updated: Thursday, July 22, 2021
In NSCLC, MET exon 14 skipping mutation (METex14) is observed in approximately 3% to 4% of cases. The approval of capmatinib and tepotinib for metastatic METex14 NSCLC has made METex14 an actionable oncogenic driver in NSCLC. In this article, the authors review the considerations for detecting METex14 in NSCLC using next-generation sequencing.
Advertisement
News & Literature Highlights
